Science
Jennifer C. King: Did You Know That IASLC PRECENT Aims to Establish pCR as an Early Clinical Endpoint?
Jennifer C. King/LinkedIn

Jennifer C. King: Did You Know That IASLC PRECENT Aims to Establish pCR as an Early Clinical Endpoint?

Jennifer C. King, Chief Science and Education Officer at International Association for the Study of Lung Cancer, shared on LinkedIn:

“Did you know that the IASLC PRECENT project aims to prove that pathologic complete response (pCR) is an early clinical endpoint?

Check out poster P1.133 from WCLC26.

Huge thanks to the steering committee:

Yu Shyr, Mark Kris, Paul Bunn, Sanja Dacic, Fred Hirsch, Mitsudomi Tetsuya, Matthew Smeltzer, Meredith Ray, Murry W. Wynes, and Matt Yeingst along with our many collaborators!.”

Title: IASLC PRECENT: Trial-Level Validation of Pathologic Complete Response (PCR) After Neoadjuvant Therapies as an Early Clinical Endpoint in NCSLC

Authors: Y. Shyr, J.C. King, M. Smeltzer, M.W. Wynes, M. Ray, T. Mitsudomi, S. Dacic, F.R. Hirsch, P.A. Bunn, M.G. Kris

Read the Full Article.

Jennifer C. King: Did You Know That IASLC PRECENT Aims to Establish pCR as an Early Clinical Endpoint?

Other articles featuring Jennifer C. King on OncoDaily.

F.R. Hirsch Fred Hirsch IASLC PRECENT J.C. King Jennifer C. King M. Ray M. Smeltzer M.G. Kris M.W. Wynes Mark Kris Matt Yeingst Matthew Smeltzer Meredith Ray Mitsudomi Tetsuya Murry W. Wynes P.A. Bunn Paul Bunn S. Dacic Sanja Dacic T. Mitsudomi WCLC26 Y. Shyr Yu Shyr